Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992571 | 0.87 | BACE1 (0.40) | BACE1 | |
| SCHEMBL21991815 | 0.84 | FBP1 (0.40) | BACE1 | |
| SCHEMBL21992573 | 0.83 | HSD17B10 (0.40) | BACE1 | |
| SCHEMBL21991505 | 0.81 | CYP1A2 (0.46) | TP53 | |
| SCHEMBL21991750 | 0.81 | CYP1A2 (0.53) | — | |
| SCHEMBL21991245 | 0.80 | MAPT (0.47) | — | |
| SCHEMBL21991306 | 0.78 | BACE1 (0.37) | PHGDHBACE1TP53 | |
| SCHEMBL21992542 | 0.77 | PPARA (0.55) | — | |
| SCHEMBL21991801 | 0.77 | PDE3B (0.42) | — | |
| SCHEMBL21992716 | 0.76 | MTNR1B (0.36) | PHGDHBACE1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PHGDH 1934/4885BACE1 1133/4885GPR139 285/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | PHGDH 1934/4885BACE1 1133/4885GPR139 285/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PHGDH 1934/4885BACE1 1133/4885GPR139 285/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PHGDH 1934/4885BACE1 1133/4885GPR139 285/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PHGDH 1934/4885BACE1 1133/4885GPR139 285/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PHGDH 1934/4885BACE1 1133/4885GPR139 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.